Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 5/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.34 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.34 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.34 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16690383 | 0.89 | NOTUM (0.38) | PTGER1PTGER4PTGER3PTGER2MAPT | |
| SCHEMBL18037158 | 0.85 | TP53 (0.36) | BRD4TP53GAAPTGER4MAPT | |
| SCHEMBL16690344 | 0.84 | PKM (0.39) | TP53GAAPTGER1PTGER4PTGER3 | |
| SCHEMBL16690362 | 0.84 | CA12 (0.35) | TP53GAAFFAR4FFAR1 | |
| SCHEMBL16690405 | 0.84 | PKM (0.43) | BRD4GAAPTGER1PTGER4PTGER3 | |
| SCHEMBL16690382 | 0.83 | FFAR1 (0.37) | BRD4FFAR1MAPT | |
| SCHEMBL16690380 | 0.83 | MRGPRX4 (0.42) | TP53GAAFFAR4FFAR1 | |
| SCHEMBL18053070 | 0.80 | KDM5A (0.34) | TP53GAAMAPT | |
| SCHEMBL16690379 | 0.80 | MAPT (0.36) | TP53MAPT | |
| SCHEMBL16690361 | 0.79 | KDM5A (0.35) | TP53GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160249617-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-09-01 | — | — | US | disclosed |
| US-20160249617-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-09-01 | — | — | US | disclosed |
| WO-2015064727-A1 | TETRAZOLINONE COMPOUND AND APPLICATION FOR SAME | 住友化学株式会社 | 2015-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160249617-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | TCOF1, TAOK2, CYC1 | SCN8A 4201/4885HTR7 3958/4885BRD4 2924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.